i would almost guarantee that SLA's sp will slide if there is a prolonged period of a lack of news.
the market cap is in blue sky territory for something that "might" be a world class drug.
remember, virtually no biotech's successfully get a drug/and or treatment to market without a long period of trials and almost inevitable hiccups.
in comparison to a stock like cmp that has revenues, is already profitable, real earnings growth prospects in the short term & a market cap of roughly 1/7th the size of SLA the huge risks in SLA are obvious.
- Forums
- ASX - By Stock
- SLA
- ropren announcement in due course
ropren announcement in due course, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)